Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux

NCT00414856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2007-06-22

No results posted yet for this study

Summary

This study will assess the safety and tolerability of oral single dose applications of AFQ056 in GERD patients.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

AFQ056

Sponsors & Collaborators

Principal Investigators

  • Novartis · Investigator site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31

Countries

  • Belgium
  • France
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414856 on ClinicalTrials.gov